KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Average (2016 - 2025)

Historic Equity Average for TherapeuticsMD (TXMD) over the last 13 years, with Q3 2025 value amounting to $27.4 million.

  • TherapeuticsMD's Equity Average fell 5.11% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year decrease of 5.11%. This contributed to the annual value of $28.3 million for FY2024, which is 1206.43% down from last year.
  • Latest data reveals that TherapeuticsMD reported Equity Average of $27.4 million as of Q3 2025, which was down 5.11% from $27.0 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Equity Average registered a high of $33.6 million during Q1 2023, and its lowest value of -$117.1 million during Q1 2022.
  • In the last 5 years, TherapeuticsMD's Equity Average had a median value of $27.1 million in 2025 and averaged -$8.0 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 27069.14% in 2021, then skyrocketed by 53676.87% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's Equity Average stood at -$75.5 million in 2021, then skyrocketed by 91.3% to -$6.6 million in 2022, then skyrocketed by 536.77% to $28.7 million in 2023, then dropped by 5.01% to $27.2 million in 2024, then grew by 0.5% to $27.4 million in 2025.
  • Its Equity Average stands at $27.4 million for Q3 2025, versus $27.0 million for Q2 2025 and $27.1 million for Q1 2025.